Despite the modest benefits observed with normal clinical doses of ACE inhibitors in slowing cardiovascular disease (CVD) end-organ damage, there is growing recognition of the incomplete blockade of RAAS as a contributing factor. The gene discussed is ACE; the disease is cardiovascular disorder.